Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 377

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 377
---
 accuracy, precision, and overall performance of its genomic services while significantly reducing costs. Our strategic vision includes the creation of AI Agents, aimed at generating additional revenue streams and providing value to pharmaceutical companies, medical institutions, and clinical labs. We plan to derive these AI Agents from pre -trainedfoundation models, designed to support diverse health management scenarios. Despite the Notice of Termination and MultiplAI SPA Termination Agreement relating to MultiplAI, we remain steadfastly committed to its long -termvision of innovating AI -drivenhealthcare solutions. The development and advancement of these technologies continue unimpacted, underscoring our unwavering dedication to their strategic goals. Rewell Improving the precision of Health Indicators, Health Reports and Actionable Habit Plans In 2023, we released a total of 18 additional indicators for Rewell, expanding our DNA and microbiome result offering to customers, based on feedback received. Currently, we are advancing a series of strategic initiatives to elevate the functionality and impact of our Rewell platform. Key enhancements include refining the user interface and the narrative quality of our health reports, with a particular focus on enriching the ancestral section for greater user engagement. We are also finalizing the local validation of polygenic risk scores for cardiovascular diseases and Type 2 Diabetes, anticipating their integration into our health assessments for more personalized health insights, which we expect to produce synergies with Clinical Diagnostic’s R&D pipeline. A customer feedback channel will also be implemented, to capture user responses on the relevance, validation, and clarity of the health indicators presented in our reports. This is part of our broader strategy to improve the interpretability of the Rewell habit plans, ensuring that they not only inform but also inspire actionable health choices. Additionally, we plan to introduce new health indicators that align with customer needs and market trends. 197 In addition, research projects are in progress that promise to introduce novel indicators and insights, with a view to further enrich our health reporting upon project completion. Concurrently, in pursuit of technical excellence, our data science team is further optimizing the precision of Rewell by developing a combination of machine learning models using several layers of datasets, derived from our users. This consented data includes genetic data, microbiome data, lifestyle data and other deep phenotyping datasets with integration of wearable analytics. Ultimately, the refinement of these models with several thousands of users datapoints will leverage an enhanced precision and better user experience in our goal to prevent disease development. Scaling Nutritional Nutrigenetic Specialists The goal is to make